Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Retained Earnings came in at -$159.1 million in Q1 2026, down 16448776.94% year-on-year from N/an in Q1 2025, and down 11.48% on a QoQ basis from -$142.7 million in Q4 2025.
Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Retained Earnings data on file, last reported at -$159.1 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 16448776.94% year-over-year to -$159.1 million in Q1 2026; TTM through Mar 2026 was -$159.1 million, a 16448776.94% decrease from a year earlier, with the FY2025 full-year figure at -$142.7 million, down 51.11% from the prior year.
- Retained Earnings for Q1 2026 stood at -$159.1 million, down from -$142.7 million in the prior quarter.
- Over the last five years, Retained Earnings for IKT reached as high as $165822.0 in Q1 2023 and fell as low as -$159.1 million in Q1 2026.
- Historically, Retained Earnings has averaged -$35.8 million across 5 years, with a median of -$2944.0 in 2025.
- Across the five-year window, Retained Earnings jumped 100.48% in 2023 and sank 16448776.94% in 2026, its largest moves.
- Year by year, Retained Earnings stood at $104718.0 in 2022, then tumbled by 99.16% to $877.0 in 2023, then plunged by 10766418.24% to -$94.4 million in 2024, then slumped by 51.11% to -$142.7 million in 2025, then dropped by 11.48% to -$159.1 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$159.1 million in Q1 2026, -$142.7 million in Q4 2025, and -$4189.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | -159.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -159.06 Mn |
| Dec 31, 2025 | -142.68 Mn |
| Sep 30, 2025 | -4,189.00 |
| Jun 30, 2025 | -2,944.00 |
| Mar 31, 2025 | -967.00 |
| Dec 31, 2024 | -94.42 Mn |
| Sep 30, 2024 | 1,754.00 |
| Jun 30, 2024 | -76.51 Mn |
| Mar 31, 2024 | -1,800.00 |
| Dec 31, 2023 | 877.00 |
| Sep 30, 2023 | -62.72 Mn |
| Jun 30, 2023 | -1,714.00 |
| Mar 31, 2023 | 165,822.00 |
| Dec 31, 2022 | 104,718.00 |
| Sep 30, 2022 | 26,828.00 |
| Jun 30, 2022 | -39.10 Mn |
| Mar 31, 2022 | -34.46 Mn |
| Dec 31, 2021 | -29.82 Mn |
| Sep 30, 2021 | -24.78 Mn |
| Jun 30, 2021 | -20.30 Mn |